Related Experiment Video

Updated: Jun 10, 2026

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
16:59

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Published on: October 10, 2012

Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector

S H Choi1, H C Lee

  • 1Department of Endocrinology and Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, Korea.

Gene Therapy
|August 20, 2010
PubMed

Insights

A novel double-stranded adeno-associated viral (dsAAV) vector delivering glucagon-like peptide-1 (GLP-1) significantly lowered blood glucose in diabetic mice. This gene therapy approach offers a long-term solution for diabetes, overcoming rapid GLP-1 inactivation.

Area of Science:

  • Endocrinology
  • Gene Therapy
  • Metabolic Diseases

Background:

  • Diabetes mellitus is marked by insulin resistance and impaired beta-cell function, leading to hyperglycemia.
  • Native glucagon-like peptide-1 (GLP-1) has therapeutic potential but suffers from rapid degradation.
  • Existing gene therapy vectors have limitations for sustained therapeutic protein expression.

Purpose of the Study:

  • To develop and evaluate a double-stranded adeno-associated viral (dsAAV) expression vector for sustained GLP-1 delivery.
  • To overcome the rapid inactivation of native GLP-1 and limitations of single-stranded AAV gene therapy.
  • To assess the efficacy and safety of dsAAV-mediated GLP-1 gene therapy in a mouse model of diabetes.

Main Methods:

  • Construction and analysis of a GLP-1 plasmid and a dsAAV expression vector.
  • Administration of a single dsAAV GLP-1 injection to db/db obese mice.
  • Monitoring of fasting blood glucose, insulin, and circulating GLP-1 levels over time.

Main Results:

  • Significant reduction in fasting blood glucose levels observed up to 4 months post-injection.
  • Increased insulin and circulating GLP-1 levels in dsAAV GLP-1-treated mice.
  • dsAAV GLP-1 demonstrated long-term transgene expression with minimal toxicity and immune response.

Conclusions:

  • dsAAV-mediated GLP-1 gene therapy is a viable strategy for long-term diabetes management.
  • This approach effectively restores glucose homeostasis and enhances insulin secretion in diabetic mice.
  • dsAAV GLP-1 offers a promising alternative to frequent GLP-1 peptide administration.

More Related Videos

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates11:24

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates

Published on: May 14, 2019

Intracranial Injection of Adeno-associated Viral Vectors08:47

Intracranial Injection of Adeno-associated Viral Vectors

Published on: November 17, 2010

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...